Beyond Grade: Molecular Pathology of Malignant Gliomas

Seminars in Radiation Oncology

Volumn 19, Issue 3, 2009, Pages 142-149

  Sulman, Erik P ^a   Guerrero, Marisol ^a   Aldape, Ken ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P14; PROTEIN P15; PROTEIN P16; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA PROTEIN; VASCULOTROPIN; WNT PROTEIN;

ASTROCYTOMA; CANCER GRADING; CARCINOGENESIS; CELL HETEROGENEITY; EPENDYMOMA; GENE AMPLIFICATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; MICROARRAY ANALYSIS; OLIGODENDROGLIOMA; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH;

BRAIN NEOPLASMS; GENE EXPRESSION PROFILING; GLIOMA; HUMANS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 65649118210     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2009.02.001     Document Type: Review

References (103)

1. In: Louis D.N., Ohgaki H., Wiestler O.D., and Cavenee W.K. (Eds). WHO Classification of Tumours of the Central Nervous System. (ed 4) (2007), International Agency for Research on Cancer, Lyon
2. Ichimura K., Ohgaki H., Kleihues P., et al. Molecular pathogenesis of astrocytic tumours. J Neurooncol 70 (2004) 137-160
3. Felsberg J., Erkwoh A., Sabel M.C., et al. Oligodendroglial tumors: Refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 14 (2004) 121-130
4. Riemenschneider M.J., Knobbe C.B., and Reifenberger G. Refined mapping of 1q32 amplicons in malignant gliomas confirms MDM4 as the main amplification target. Int J Cancer 104 (2003) 752-757
5. Eley G.D., Reiter J.L., Pandita A., et al. A chromosomal region 7p11.2 transcript map: Its development and application to the study of EGFR amplicons in glioblastoma. J Neurooncol 4 (2002) 86-94
6. Rasheed B.K., McLendon R.E., Friedman H.S., et al. Chromosome 10 deletion mapping in human gliomas: A common deletion region in 10q25. Oncogene 10 (1995) 2243-2246
7. Kitange G., Misra A., Law M., et al. Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas. Genes Chromosomes Cancer 42 (2005) 68-77
8. Reifenberger J., Reifenberger G., Liu L., et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145 (1994) 1175-1190
9. Reifenberger G., and Louis D.N. Oligodendroglioma: Toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 62 (2003) 111-126
10. Hartmann C., Johnk L., Kitange G., et al. Transcript map of the 3.7-Mb D19S112-D19S246 candidate tumor suppressor region on the long arm of chromosome 19. Cancer Res 62 (2002) 4100-4108
11. Smith J.S., Tachibana I., Pohl U., et al. A transcript map of the chromosome 19q-arm glioma tumor suppressor region. Genomics 64 (2000) 44-50
12. Huang B., Starostik P., Kuhl J., et al. Loss of heterozygosity on chromosome 22 in human ependymomas. Acta Neuropathol 103 (2002) 415-420
13. Suarez-Merino B., Hubank M., Revesz T., et al. Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3. J Neurooncol 7 (2005) 20-31
14. Oskam N.T., Bijleveld E.H., and Hulsebos T.J. A region of common deletion in 22q13.3 in human glioma associated with astrocytoma progression. Int J Cancer 85 (2000) 336-339
15. Ino Y., Silver J.S., Blazejewski L., et al. Common regions of deletion on chromosome 22q12.3-q13.1 and 22q13.2 in human astrocytomas appear related to malignancy grade. J Neuropathol Exp Neurol 58 (1999) 881-885
16. Boon K., Edwards J.B., Siu I.M., et al. Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes. Oncogene 22 (2003) 7687-7694
17. Rasheed B.K., Wiltshire R.N., Bigner S.H., et al. Molecular pathogenesis of malignant gliomas. Curr Opin Oncol 11 (1999) 162-167
18. Lang F.F., Miller D.C., Koslow M., et al. Pathways leading to glioblastoma multiforme: A molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 81 (1994) 427-436
19. Kleihues P., and Ohgaki H. Phenotype vs genotype in the evolution of astrocytic brain tumors. Toxicol Pathol 28 (2000) 164-170
20. Ohgaki H., Dessen P., Jourde B., et al. Genetic pathways to glioblastoma: A population-based study. Cancer Res 64 (2004) 6892-6899
21. Nigro J.M., Takahashi M.A., Ginzinger D.G., et al. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol 158 (2001) 1253-1262
22. Freije W.A., Castro-Vargas F.E., Fang Z., et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64 (2004) 6503-6510
23. Phillips H.S., Kharbanda S., Chen R., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cells 9 (2006) 157-173
24. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 (2008) 1061-1068
25. Wiencke J.K., Aldape K., McMillan A., et al. Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase. Cancer Epidemiol Biomarkers Prev 14 (2005) 1774-1783
26. Kleihues P., Schauble B., Zur Hausen A., et al. Tumors associated with p53 germline mutations: A synopsis of 91 families. Am J Pathol 150 (1997) 1-13
27. James C.D., Smith J.S., and Jenkins R.B. Genetic and molecular basis of primary central nervous system tumors. In: Levin V.A. (Ed). Cancer in the nervous system (2002), Oxford University Press, NY 239-251
28. Lang F.F., Miller D.C., Pisharody S., et al. High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas. Oncogene 9 (1994) 949-954
29. von Deimling A., Eibl R.H., Ohgaki H., et al. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res 52 (1992) 2987-2990
30. Okada Y., Hurwitz E.E., Esposito J.M., et al. Selection pressures of TP53 mutation and microenvironmental location influence epidermal growth factor receptor gene amplification in human glioblastomas. Cancer Res 63 (2003) 413-416
31. Beaty R.M., Edwards J.B., Boon K., et al. PLXDC1 (TEM7) is identified in a genome-wide expression screen of glioblastoma endothelium. J Neurooncol 81 (2007) 241-248
32. Boon K., and Riggins G.J. SAGE as a strategy to isolate cancer-related genes. Methods Mol Biol 222 (2003) 463-479
33. Kavsan V.M., Dmitrenko V.V., Shostak K.O., et al. Comparison of microarray and sage techniques in gene expression analysis of human glioblastoma. Tsitol Genet 41 (2007) 36-55
34. Ljubimova J.Y., Khazenzon N.M., Chen Z., et al. Gene expression abnormalities in human glial tumors identified by gene array. Int J Oncol 18 (2001) 287-295
35. CBTRUS (2008). Statistical Report: Primary Brain Tumors in the United States, 2000-2004. Published by the Central Brain Tumor Registry of the United States
36. Behin A., Hoang-Xuan K., Carpentier A.F., et al. Primary brain tumours in adults. Lancet 361 (2003) 323-331
37. Kleihues P., Collins V.P., Newcomb E.W., et al. Glioblastoma. In: Kleihues P.C.W. (Ed). Pathology and Genetics of Tumours of the Nervous System. (ed 1) (2000), International Agency for Research on Cancer (IARC) Press, Lyon, France 29-39
38. Kulesh D.A., Clive D.R., Zarlenga D.S., et al. Identification of interferon-modulated proliferation-related cDNA sequences. Proc Natl Acad Sci U S A 84 (1987) 8453-8457
39. Schena M., Shalon D., Davis R.W., et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270 (1995) 467-470
40. Lashkari D.A., DeRisi J.L., McCusker J.H., et al. Yeast microarrays for genome wide parallel genetic and gene expression analysis. Proc Natl Acad Sci U S A 94 (1997) 13057-13062
41. Bammler T., Beyer R.P., Bhattacharya S., et al. Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods 2 (2005) 351-356
42. Pease A.C., Solas D., Sullivan E.J., et al. Light-generated oligonucleotide arrays for rapid DNA sequence analysis. Proc Natl Acad Sci U S A 91 (1994) 5022-5026
43. Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 (2000) 503-511
44. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
45. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98 (2001) 10869-10874
46. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A100 (2003) 8418-8423
47. Baker J. Genomic Health, Inc. Pharmacogenomics 8 (2007) 397-399
48. Glas A.M., Floore A., Delahaye L.J., et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genom 7 (2006) 278
49. Eisen M.B., and Brown P.O. DNA arrays for analysis of gene expression. Methods Enzymol 303 (1999) 179-205
50. Eisen M.B., Spellman P.T., Brown P.O., et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95 (1998) 14863-14868
51. Tavazoie S., Hughes J.D., Campbell M.J., et al. Systematic determination of genetic network architecture. Nat Genet 22 (1999) 281-285
52. Allison D.B., Cui X., Page G.P., et al. Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genet 7 (2006) 55-65
53. Michiels S., Koscielny S., and Hill C. Interpretation of microarray data in cancer. Br J Cancer 96 (2007) 1155-1158
54. Fuller G.N., Rhee C.H., Hess K.R., et al. Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: A revelation by parallel gene expression profiling. Cancer Res 59 (1999) 4228-4232
55. Caskey L.S., Fuller G.N., Bruner J.M., et al. Toward a molecular classification of the gliomas: Histopathology, molecular genetics, and gene expression profiling. Histol Histopathol 15 (2000) 971-981
56. Huang H., Colella S., Kurrer M., et al. Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays. Cancer Res 60 (2000) 6868-6874
57. Sallinen S.L., Sallinen P.K., Haapasalo H.K., et al. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 60 (2000) 6617-6622
58. Chakravarti A., Delaney M.A., Noll E., et al. Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res 7 (2001) 2387-2395
59. Somasundaram K., Reddy S.P., Vinnakota K., et al. Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma. Oncogene 24 (2005) 7073-7083
60. Raza S.M., Fuller G.N., Rhee C.H., et al. Identification of necrosis-associated genes in glioblastoma by cDNA microarray analysis. Clin Cancer Res 10 (2004) 212-221
61. Rickman D.S., Bobek M.P., Misek D.E., et al. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res 61 (2001) 6885-6891
62. Dai B., Kang S.H., Gong W., et al. Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells. Oncogene 26 (2007) 6212-6219
63. Liu M., Dai B., Kang S.H., et al. FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res 66 (2006) 3593-3602
64. Teh M.T., Wong S.T., Neill G.W., et al. FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res 62 (2002) 4773-4780
65. van den Boom J., Wolter M., Kuick R., et al. Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol 163 (2003) 1033-1043
66. Cheung H.C., Baggerly K.A., Tsavachidis S., et al. Global analysis of aberrant pre-mRNA splicing in glioblastoma using exon expression arrays. BMC Genom 9 (2008) 216
67. French P.J., Peeters J., Horsman S., et al. Identification of differentially regulated splice variants and novel exons in glial brain tumors using exon expression arrays. Cancer Res 67 (2007) 5635-5642
68. Tanwar M.K., Gilbert M.R., and Holland E.C. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 62 (2002) 4364-4368
69. Khatua S., Peterson K.M., Brown K.M., et al. Overexpression of the EGFR/FKBP12/HIF-2alpha pathway identified in childhood astrocytomas by angiogenesis gene profiling. Cancer Res 63 (2003) 1865-1870
70. Liang Y., Diehn M., Watson N., et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A 102 (2005) 5814-5819
71. Nigro J.M., Misra A., Zhang L., et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 65 (2005) 1678-1686
72. Liu F., Park P.J., Lai W., et al. A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma. Cancer Res 66 (2006) 10815-10823
73. Faury D., Nantel A., Dunn S.E., et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol 25 (2007) 1196-1208
74. McDonald K.L., O'Sullivan M.G., Parkinson J.F., et al. IQGAP1 and IGFBP2: Valuable biomarkers for determining prognosis in glioma patients. J Neuropathol Exp Neurol 66 (2007) 405-417
75. Reddy S.P., Britto R., Vinnakota K., et al. Novel glioblastoma markers with diagnostic and prognostic value identified through transcriptome analysis. Clin Cancer Res 14 (2008) 2978-2987
76. Ruano Y., Mollejo M., Camacho F.I., et al. Identification of survival-related genes of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma multiforme. Cancer 112 (2008) 1575-1584
77. Scrideli C.A., Carlotti Jr. C.G., Okamoto O.K., et al. Gene expression profile analysis of primary glioblastomas and non-neoplastic brain tissue: Identification of potential target genes by oligonucleotide microarray and real-time quantitative PCR. J Neurooncol 88 (2008) 281-291
78. Nutt C.L., Betensky R.A., Brower M.A., et al. YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clin Cancer Res 11 (2005) 2258-2264
79. Pelloski C.E., Mahajan A., Maor M., et al. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res 11 (2005) 3326-3334
80. Pelloski C.E., Lin E., Zhang L., et al. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res 12 (2006) 3935-3941
81. Persson O., Krogh M., Saal L.H., et al. Microarray analysis of gliomas reveals chromosomal position-associated gene expression patterns and identifies potential immunotherapy targets. J Neurooncol 85 (2007) 11-24
82. Bozinov O., Kohler S., Samans B., et al. Candidate genes for the progression of malignant gliomas identified by microarray analysis. Neurosurg Rev 31 (2008) 83-89
83. Czernicki T., Zegarska J., Paczek L., et al. Gene expression profile as a prognostic factor in high-grade gliomas. Int J Oncol 30 (2007) 55-64
84. Godard S., Getz G., Delorenzi M., et al. Classification of human astrocytic gliomas on the basis of gene expression: A correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 63 (2003) 6613-6625
85. Kim S., Dougherty E.R., Shmulevich I., et al. Identification of combination gene sets for glioma classification. Mol Cancer Ther 1 (2002) 1229-1236
86. Margareto J., Leis O., Larrarte E., et al. Gene expression profiling of human gliomas reveals differences between GBM and LGA related to energy metabolism and notch signaling pathways. J Mol Neurosci 32 (2007) 53-63
87. Nutt C.L., Mani D.R., Betensky R.A., et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63 (2003) 1602-1607
88. Pomeroy S.L., Tamayo P., Gaasenbeek M., et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415 (2002) 436-442
89. Shai R., Shi T., Kremen T.J., et al. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 22 (2003) 4918-4923
90. Watson M.A., Perry A., Budhraja V., et al. Gene expression profiling with oligonucleotide microarrays distinguishes World Health Organization grade of oligodendrogliomas. Cancer Res 61 (2001) 1825-1829
91. Mukasa A., Ueki K., Matsumoto S., et al. Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p. Oncogene 21 (2002) 3961-3968
92. Huang H., Okamoto Y., Yokoo H., et al. Gene expression profiling and subgroup identification of oligodendrogliomas. Oncogene 23 (2004) 6012-6022
93. Mukasa A., Ueki K., Ge X., et al. Selective expression of a subset of neuronal genes in oligodendroglioma with chromosome 1p loss. Brain Pathol 14 (2004) 34-42
94. French P.J., Swagemakers S.M., Nagel J.H., et al. Gene expression profiles associated with treatment response in oligodendrogliomas. Cancer Res 65 (2005) 11335-11344
95. Tews B., Felsberg J., Hartmann C., et al. Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. Int J Cancer 119 (2006) 792-800
96. Ducray F., Idbaih A., de Reynies A., et al. Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer 7 (2008) 41
97. Hagerstrand D., Smits A., Eriksson A., et al. Gene expression analyses of grade II gliomas and identification of rPTPbeta/zeta as a candidate oligodendroglioma marker. J Neurooncol 10 (2008) 2-9
98. Cairncross J.G., Ueki K., Zlatescu M.C., et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90 (1998) 1473-1479
99. Petalidis L.P., Oulas A., Backlund M., et al. Improved grading and survival prediction of human astrocytic brain tumors by artificial neural network analysis of gene expression microarray data. Mol Cancer Ther 7 (2008) 1013-1024
100. Parsons D.W., Jones S., Zhang X., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321 (2008) 1807-1812
101. McLendon R., Friedman A., Bigner D., et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 (2008) 1061-1068
102. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 (2004) 2817-2826
103. van de Vijver M.J., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 (2002) 1999-2009